Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q3 2025 · 10-Q
Revenue$70.24K$70.24K−6.3% vs Q3 2024 Net Income-$523.52K-$523.52KN/M vs Q3 2024 EPS Diluted$0.00$0.00— vs Q3 2024 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Operating Cash Flowderived-$250,770N/M Free Cash Flowderived-$250,770— Margins · derivedGross margin91.9%−2.3 pt vs Q3 2024
Operating margin-506.9%−260.6 pt vs Q3 2024
Net margin-745.3%−397.7 pt vs Q3 2024
ended Sep 30, 2025 · filed Apr 6, 2026 · 188 d after period end